Compare ARDX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | MAX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 657.4M |
| IPO Year | 2014 | 2020 |
| Metric | ARDX | MAX |
|---|---|---|
| Price | $3.02 | $14.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $12.80 | ★ $15.71 |
| AVG Volume (30 Days) | ★ 4.3M | 1.0M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.81 |
| EPS | N/A | ★ 1.32 |
| Revenue | $2,607,000.00 | ★ $1,113,600,000.00 |
| Revenue This Year | $19.21 | $21.30 |
| Revenue Next Year | $28.19 | $11.16 |
| P/E Ratio | ★ N/A | $11.03 |
| Revenue Growth | N/A | ★ 28.78 |
| 52 Week Low | $2.96 | $7.09 |
| 52 Week High | $8.40 | $14.87 |
| Indicator | ARDX | MAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 76.72 |
| Support Level | N/A | $8.01 |
| Resistance Level | $3.35 | N/A |
| Average True Range (ATR) | 0.13 | 0.69 |
| MACD | 0.01 | 0.42 |
| Stochastic Oscillator | 15.19 | 96.34 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.